RxDoctor Payments Data

Bhupinder Khehar, MD

Internal Medicine · San Diego, CANPI 1831151992

Payments from drug & device makers

$183in general payments, 2019–2025

Across 5 payments — averaging $36.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$99
  • Lilly USA, LLC$26
  • GSK$22
  • Mylan Specialty L.p.$20
  • Novo Nordisk$17

What the payments were for

  • Food & beverage$183100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$183 in reported general payments places this provider in the 50th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$301,733
Medicare patients
388
Services billed
2,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$99,701
JanuviaSitagliptin Phosphate90$95,004
JardianceEmpagliflozin51$66,110
MounjaroTirzepatide33$47,444
TriumeqAbacavir/Dolutegravir/Lamivudi13$47,207
TrulicityDulaglutide27$42,176
OzempicSemaglutide33$37,338
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$20,156
XareltoRivaroxaban11$16,762
Breo ElliptaFluticasone/Vilanterol19$15,542
Levemir FlexpenInsulin Detemir19$6,740
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$6,191
Atorvastatin Calcium560$5,591
Nebivolol Hcl76$4,833
Losartan Potassium336$3,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$26$89,62060 claims
Novo NordiskOzempic$17$37,33833 claims
GSKTrelegy Ellipta, Breo Ellipta$22$35,69835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →